What it's for (Indications)
- Glipizide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- It is classified as a sulfonylurea and primarily works by stimulating the pancreas to release more insulin.
- This medication is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as these conditions involve an absolute or severe lack of insulin production.
- The initiation of glipizide therapy should be carefully considered within a comprehensive diabetes management plan, which includes lifestyle modifications like dietary management, weight reduction, and regular physical activity, all of which are crucial for achieving optimal glycemic control in type 2 diabetes.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of glipizide must be individualized based on the patient's glycemic response and tolerance. For glipizide immediate-release tablets, the recommended starting dose is 5 mg once daily, administered approximately 30 minutes before a meal, typically breakfast. If necessary, dosage adjustments should be made in increments of 2.5 to 5 mg at intervals of several days, up to a maximum recommended dose of 40 mg per day. Doses exceeding 15 mg daily should generally be divided and given before meals. For glipizide extended-release tablets (XL), the recommended starting dose is also 5 mg once daily, taken with breakfast. Dosage adjustments for the extended-release formulation should be made in 5 mg increments at weekly intervals, with a maximum recommended dose of 20 mg once daily. Dose reduction may be necessary in elderly patients or those with impaired hepatic or renal function due to increased risk of hypoglycemia. Always refer to the specific product information for complete dosing guidelines. |
Safety & Warnings
Common Side Effects
- Common side effects associated with glipizide include hypoglycemia, which is the most significant and frequent adverse event, especially if meals are delayed, inadequate, or combined with vigorous exercise or alcohol intake.
- Other common adverse reactions may involve the gastrointestinal system, such as nausea, diarrhea, constipation, and dyspepsia.
- Dermatological reactions like rash, urticaria, and pruritus have been reported, and photosensitivity may occur.
- Less common but more serious side effects include cholestatic jaundice, which necessitates immediate discontinuation, and hematologic abnormalities suchations such as leukopenia, thrombocytopenia, aplastic anemia, agranulocytosis, and hemolytic anemia.
- Hyponatremia has also been reported.
- Patients should be educated on the symptoms of hypoglycemia (e.
- g.
- , sweating, dizziness, confusion, hunger, tremor) and how to manage them promptly to prevent severe complications.
Serious Warnings
- Black Box Warning: Serious Warnings: Cardiovascular Mortality. Although glipizide does not carry a formal FDA Black Box Warning, a serious warning regarding increased cardiovascular mortality historically associated with sulfonylurea treatment warrants careful consideration. The University Group Diabetes Program (UGDP) study, a landmark trial conducted in the 1960s, reported an elevated risk of cardiovascular death in patients with non-insulin-dependent diabetes treated with tolbutamide, a first-generation sulfonylurea, compared to diet alone or diet plus insulin. While subsequent studies involving second-generation sulfonylureas like glipizide have not definitively confirmed this increased risk to the same extent, the UGDP findings have cast a long-standing concern over the entire sulfonylurea class. Clinicians should carefully assess the potential risks and benefits of glipizide, particularly in patients with pre-existing cardiovascular disease. Monitoring for signs of cardiovascular complications and exploring alternative antidiabetic therapies may be prudent in high-risk individuals, as part of a comprehensive and individualized treatment strategy for type 2 diabetes.
- Glipizide carries several important warnings.
- The most prominent risk is hypoglycemia, which can be severe and life-threatening, particularly in elderly, debilitated, or malnourished patients, and those with adrenal or pituitary insufficiency, or hepatic and renal impairment.
- Concurrent use of alcohol or certain medications (e.
- g.
- , beta-blockers, fluconazole, NSAIDs) can potentiate the hypoglycemic effect.
- Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency are at risk of hemolytic anemia with sulfonylurea treatment, thus caution is advised.
- There is a potential for loss of glycemic control over time, known as secondary failure, which may necessitate adjustment of therapy or addition of other antidiabetic agents.
- Patients should be carefully monitored for signs of hepatic or renal dysfunction, as these conditions can significantly alter glipizide metabolism and excretion, increasing the risk of adverse events.
- Careful patient selection and education are paramount to mitigate these risks.
How it Works (Mechanism of Action)
Glipizide is a second-generation sulfonylurea antidiabetic agent that exerts its primary action by stimulating insulin release from the pancreatic beta cells. Its mechanism involves binding to the sulfonylurea receptor (SUR1) subunit of the ATP-sensitive potassium (KATP) channel located on the beta-cell membrane. This binding leads to the closure of these KATP channels, which reduces the efflux of potassium ions from the cell. The subsequent accumulation of intracellular potassium causes depolarization of the beta-cell membrane. This depolarization, in turn, opens voltage-gated calcium channels, allowing an influx of calcium ions into the cell. The elevated intracellular calcium concentration is the critical signal that triggers the fusion of insulin-containing secretory granules with the cell membrane, thereby promoting the exocytosis and release of preformed insulin into the systemic circulation. This process is largely dependent on the presence of functioning pancreatic beta cells and is enhanced by glucose, leading to improved glycemic control.